急性缺血性卒中溶栓相關(guān)因素分析

急性缺血性卒中溶栓治療相關(guān)因素分析2022/12/27湘雅二醫(yī)院神經(jīng)內(nèi)科定義湘雅二醫(yī)院神經(jīng)內(nèi)科腦梗死：指因腦部血流循環(huán)障礙、缺血、缺氧所致的局限性腦組織的缺血性壞死或軟化。溶栓治療：靜脈溶栓、動(dòng)脈溶栓及機(jī)械取栓等治療。

ThecentralpathophysiologicalhypothesisunderlyingAIStherapyisthatafteracerebralarterybecomesoccluded,thereissomeamountofhypoperfusedbraintissueatriskfor

permanentinfarctionthatcouldbesalvagedbyexpeditiousrestorationofbloodflow.湘雅二醫(yī)院神經(jīng)內(nèi)科治療目的PreventingtheischemicpenumbrafromprogressingtoirreversibleinfarctionisthegoalofacutereperfusiontherapySchematicrepresentationofregionsofhypoperfusedbraintissuefollowingacuteocclusionofthemiddlecerebralartery.Theischemiccoreisanareaofirreversibleischemiaandcelldeath;

ischemicpenumbra,potentiallysalvageabletissuewithpromptreperfusion;benignoligemia,decreasedperfusionbutnoinfarctionriskregardlessoftreatment.Theinfarctcorecanenlargeintothepenumbraifreperfusionisnotsuccessful.缺血半暗帶Diffusion-weightedimagediffusion-weightedMRIshowingahyperintensityconsistentwithirreversibleischemia(ischemiccore)inthedeepperforatingterritoryoftherightmiddlecerebralarteryaffectingthecaudate,internalcapsule,andlentiformnucleus.PWIatthesamelevelastheDWIshowedamuchlargerareaofhypoperfusion.PWIusescontrastmaterialtoestimatecerebralbloodflow.Thecolorscalerepresentsmeantransittimeofacontrastbolus;blueindicatesnormaltransittimeandshadesofgreen,yellow,orange,andredindicatedelayintransittime(ischemia).TheregionoftheischemiccoreasdefinedintheDWIshowsareasofnocontrast(black)inthePWI,indicativeofirreversibleinjury.Perfusion-weightedimage缺血半暗帶湘雅二醫(yī)院神經(jīng)內(nèi)科Overthefirstfewminutestohoursafteranacutearterialocclusion,ischemicpenumbraltissueprogressestoaninfarctcore.Itisestimatedthatforeveryminuteanarteryisoccludedduringanischemicstroke,2millionneuronsdie,whichover10hoursisequivalenttotheexpectedneuronallossoccurringwith26yearsofnormalaging.thepotentialbenefitofrestoringbloodflowreducesovertime.

再灌注治療湘雅二醫(yī)院神經(jīng)內(nèi)科Strategiestorapidlyreperfusebraintissueatriskofinfarctionincludeintravenousandintra-arterialadministrationofthrombolyticdrugsandtheuseofvariousthrombectomydevicesunderangiographicandfluoroscopicguidancethrombolyticdrugs靜脈溶栓機(jī)制Thrombolyticagentsaimatdisruptingthefibrin-richclotthatiscreatedinresponsetoinjuryoftheendothelium.Byactivatingplasminogen,theadministrationofthrombolyticsleadstoanincreasedproductionofplasmin,whichdissolvesthefibrinbondsintheclot.湘雅二醫(yī)院神經(jīng)內(nèi)科In1995,theNINDS(NationalInstituteofNeurologicalDisordersandStroke)tPA(tissueplasminogenactivator)StrokeStudyGrouppublishedtheresultsofalargemulticenterclinicaltrialdemonstratingefficacyofintravenoustPAbyrevealinga30%relativeriskreduction(absoluteriskreduction11%–15%)comparedwithplaceboat90daysinthelikelihoodofhavingminimalornodisability.Sinceapprovalin1996,tPAremainstheonlydrugtreatmentforacuteischemicstrokeapprovedbytheUSFoodandDrugAdministration.靜脈溶栓靜脈溶栓湘雅二醫(yī)院神經(jīng)內(nèi)科strokeremainsaleadingcauseofseriouslong-termdisabilityanddeathworldwide；almost20yearssinceitsapproval,anabundanceofresearchandclinicaldatahassupportedthesafeandefficacioususeofintravenoustPAinalleligiblepatients.itremainssubstantiallyunderutilizedIVtPA,yethighlyefficaciousfirst-linetreatment.湘雅二醫(yī)院神經(jīng)內(nèi)科ChallengestotheutilizationoftPAinclude：①narroweligibilityandtreatmentwindows;②riskofsymptomaticintracerebralhemorrhage;③perceivedlackofefficacyincertainhigh-risksubgroups;④alimitedpoolofneurologicalandstrokeexpertiseinthecommunity.ChallengestotheutilizationoftPA相對禁忌癥湘雅二醫(yī)院神經(jīng)內(nèi)科3小時(shí)內(nèi)溶栓1、輕型或快速改善的卒中2、妊娠3、癲癇發(fā)作后出現(xiàn)的神經(jīng)功能損害癥狀4、近2周內(nèi)有大型外科手術(shù)或嚴(yán)重外傷5、近3周內(nèi)有胃腸道或泌尿系出血6、近3個(gè)月內(nèi)有心肌梗死史相對禁忌癥湘雅二醫(yī)院神經(jīng)內(nèi)科3-4.5小時(shí)內(nèi)溶栓1、年齡大于80歲2、嚴(yán)重卒中（NIHSS評分大于25分）3、口服抗凝藥物（不考慮INR水平）4、有糖尿病和缺血性卒中病史湘雅二醫(yī)院神經(jīng)內(nèi)科Theimportanceoftime-totreatmentwitheverypassingminuteuntilreperfusionisachieved,about2millionneuronsand14billionsynapsesarelost.

Mostrecently,astudyof58,353tPA-treatedpatientshighlightedthatforevery15-minuteimprovementintime-to-treatment,patientswerelesslikelytodie，experiencesICHandweremorelikelytobeambulatoryatdischarge;湘雅二醫(yī)院神經(jīng)內(nèi)科Theimportanceoftime-totreatmentBasedonthemostcurrent2013AHA/ASAguidelineupdateregardingfibrinolysisinacutestroke,tPAisrecommendedforeligiblepatientswhopresentwithin3hoursofstrokeonsetandupto4.5hoursineligiblepatients;thefollowingadditionalexclusions:patients>80yearsofage,thosetakingoralanticoagulantsregardlessofinternationalnormalizedratio(INR),baselineNIHSS>25,thosewithimagingevidenceofischemicinjuryinvolvingmorethanonethirdofthemiddlecerebralarteryterritory,andthosewithahistoryofbothstrokeanddiabetesmellitus湘雅二醫(yī)院神經(jīng)內(nèi)科ThebenefitsandrisksofIVthrombolysisincertainsubgroupsMildandrapidlyimprovingstrokes湘雅二醫(yī)院神經(jīng)內(nèi)科

mildand/orrapidlyimprovingstrokeswillfollowanaturalcourseoffavorablefunctionaloutcomeinspiteofacceptingtheadditionalriskoftPA.alarge-vesselocclusiononmagneticresonanceangiographycorrespondingtotheacutestrokein33%ofpatientsexcludedfromtPAduetoRIMS.28.3%ofuntreatedpatientswithRIMSnotdischargedhomeand28.5%unabletoambulatewithoutassistanceatdischarge.Mildandrapidlyimprovingstrokes湘雅二醫(yī)院神經(jīng)內(nèi)科Whereasalloftheabovestudiesevaluatedoutcomesattimeofdischarge,Nedeltchevetalevaluated3-monthoutcomesforuntreatedpatientswithRIMSandfoundthat75%hadafavorableoutcome;threesmallstudieshaveshownasignificantimprovementinclinicaloutcomewithnoincreasedriskofhemorrhageintPA-treatedRIMSpatients;Athirdofthepatientspresentingwithischemicstrokeareovertheageof80;

elderlypatientsmaybeatanincreasedriskofICHduetocerebralamyloidangiopathy,impairedrenalclearance,andfrailvasculature;Manyclinicianswithholdtreatmentduetofearthatageisassociatedwithpoorprognosisandincreasedriskofhemorrhage;湘雅二醫(yī)院神經(jīng)內(nèi)科OlderageOlderageOfthe49patientsovertheageof75includedintheNINDStPAtrial,outcomewasrelatedtoage-by-neurologicdeficitbutdidnotaltertreatmenteffect.Inaddition,agedidnotindependentlyincreasetheriskofhemorrhage.TheThirdInternationalStrokeTrial(IST-3)wasthefirstprospectiverandomizedtrialtoincludeasizablenumberofpatients﹥80years(53%).AsubgroupanalysisfromIST-3suggestedagreaterbenefitfromtPAinpatientsolderthan80comparedwiththeiryoungercounterparts(P=0.027).Basedontheseresults,tPAshouldnotbewithheldbasedpurelyonage,andinfact,patientsolderthan80maydoaswellifnotbetterwithtreatmentcomparedwithcontrol.StrokemimicsStrokemimicsTheneedforrapidrecognitionandtreatmentofAISpotentiatesthelikelihoodofadministeringtPAtoastrokemimic;ThefractionofstrokemimicsamongtPA-treatedpatientsinvariouscohortshasbeenreportedbetween1%and31%,withcommunityhospitalsreportingratesashighas25%–29%;thesepercentagesreflectthelackofstandardmimicdefinitionsand/orinaccuraciesindiagnosisreporting;Commoncharacteristicsofstrokemimicsareyoungage,femalesex,noorfewbaselineriskfactors,lefthemisphericsyndromes,andmilderpresentingstrokeseverity.aphasia,particularlywhenglobalandnotpresentingwithanyotherdeficits,isoneofthemostcommonlycitedpresentationsofstrokemimics;ThesafetyoftPAinstrokemimicswasevaluatedinamulticenterobservationalstudythatrevealedansICHrateof1.0%(CI0.0–5.0)inmimicscomparedwith7.9%(CI7.2–8.7)inimaging-confirmedischemicstroke;treatedstrokemimicsweremorelikelytoexperienceanexcellentoutcomeat3monthscomparedwithAIS(75%versus39.5%;P,0.0001)湘雅二醫(yī)院神經(jīng)內(nèi)科Strokemimics35%ofAISpatientseligibleforreperfusiontherapiesareunderanantiplateletregimen.TheproportionofsICHinpatientstreatedwithantiplatelettherapywithintheprevious48hourswas9%forthoseallocatedr-tPAversus1%incontrol,comparedwith5%forr-tPAand1%controlforthosewithnorecentantiplatelettherapy.Priorantiplateletuseandclinicaloutcome

whenmultivariateanalyseswereconducted,priorantiplateletusewasnotassociatedwithICHincreasedrisk,aswellas,withotherclinicaloutcomes;Priorantiplateletusehastobeconsideredasanindicatorofpastvasculardisease,whichisbyitselfassociatedwithunfavorableoutcome;nosignificantdifferencewasfoundinhemorrhagiccomplicationand90-daymortalityratesaccordingtopriorantiplateletuseInsummary,onthebasisofavailableliterature,priorantiplateletuseshouldnotconsideredasacriterionofineligibilityforanyAISrevascularization.

PriorantiplateletuseTheaimsoftheThirdInternationalStrokeTrial(IST-3)weretoestablishwhetherawidergroupofpatientswouldbenefitfromstrokethrombolysisandwhichcategoriesofpatientsweremostlikelytobenefitorbeharmedbytreatment.

AlteplaseforAcuteIschemicStrokeOutcomesbyClinicallyImportantSubgroupsintheThirdInternationalStrokeTrialIST-3recruited3035patientswhowererandomizedtor-tPAorcontrolwithin6hoursofstrokeonset;themainresultsandprincipalprespecifiedsubgroupanalyseshavebeenpreviouslypublished.StrokeonJuly3,2016patientshadtomeetthefollowingcriteria:1.symptomsandsignsofclinicallydefiniteacutestroke;2.thetimeofstrokeonsetwasknown;3.treatmentcouldbestartedwithin6hoursofonset;4.CTorMRIhadreliablyexcludedbothintracranialhemorrhageandstructuralbrainlesions,whichcouldmimicstroke(eg,cerebraltumor);

BeforeIST-3,dataaboutthefrequencyofhemorrhagictransformationofcerebralinfarctioninthenaturalhistoryofuntreatedstroke:largevolumesofinfarction,masseffect,earlytissuehypoattenuation,andolderage(age>70years);

recentsystematicreviewofsICHinpatientstreatedwiththrombolysis:highplasmaglucose;prioruseofaspirin;statins;leukoariosisis;atrialfibrillation;diabetesmellitus;previousischemicheartdisease;previouscerebralvasculardisease;andcongestivecardiacfailure.StrokeonJuly3,2016themajorrisksofhemorrhagictransformationweonlyobservedamarginallysignificantinteractiononsICHwithpriorantiplateletuse,mainlyattributabletoprioraspirinuse;butthiswasnotassociatedwithaneffecton6-monthfunctionaloutcome.Oneexplanationforthismightbeasaresultofacounterbalancinglaterbenefitofantiplatelettreatment,perhapsbymaintainingvesselpatencyaftersuccessfulrecanalizationthemarginallysignificantrisksWewereunabletoidentifyanyparticularsubgroupwithanegligibleriskofsICH,eventhosewithstrokeseverityofNIHSS<6wereobservedtohaveane